In the last trading session, 1.04 million shares of the Corvus Pharmaceuticals Inc (NASDAQ:CRVS) were traded, and its beta was 0.57. Most recently the company’s share price was $3.93, and it changed around -$0.32 or -7.53% from the last close, which brings the market valuation of the company to $252.53M. CRVS currently trades at a discount to its 52-week high of $10.00, offering almost -154.45% off that amount. The share price’s 52-week low was $1.30, which indicates that the current value has risen by an impressive 66.92% since then. We note from Corvus Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 0.56 million shares, with the 3-month average coming to 581.22K.
Corvus Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended CRVS as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Corvus Pharmaceuticals Inc is expected to report earnings per share of -0.12 for the current quarter.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) trade information
Instantly CRVS has showed a red trend with a performance of -7.53% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.75 on recent trading dayincreased the stock’s daily price by 17.26%. The company’s shares are currently down -26.54% year-to-date, but still down -16.20% over the last five days. On the other hand, Corvus Pharmaceuticals Inc (NASDAQ:CRVS) is -3.91% down in the 30-day period. We can see from the shorts that 5.35 million shares have been sold at a short interest cover period of 10.26 day(s).
The consensus price target as assigned by Wall Street analysts is $12.5, which translates to bulls needing to increase their stock price by 68.56% from its current value. Analyst projections state that CRVS is forecast to be at a low of $12 and a high of $13.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 19.89%. Corvus Pharmaceuticals Inc earnings are expected to increase by 54.90% in 2025, but the outlook is positive 16.84% per year for the next five years.
CRVS Dividends
Corvus Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2024-Nov-11.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.44% of Corvus Pharmaceuticals Inc shares, and 58.77% of them are in the hands of institutional investors. The stock currently has a share float of 60.87%. Corvus Pharmaceuticals Inc stock is held by 102.0 institutions, with ORBIMED ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 11.6289% of the shares, which is about 6.94 million shares worth $12.64 million.
SAMLYN CAPITAL, LLC, with 10.2546% or 6.12 million shares worth $11.14 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.58 shares worth $6.22 million, making up 2.46% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 793.14 shares worth around $3.12 million, which represents about 1.23% of the total shares outstanding.
